TriMas schedules Q3FY26 earnings call for Oct 29 at 10 am ET
- TriMas will hold its Q3FY26 earnings call on Oct 29 at 10 am ET
- Results release scheduled for 8:00 am ET same day
- Replay available from Oct 29 to Nov 11 via phone or webcast

*this image is generated using AI for illustrative purposes only.
TriMas announced that it will hold its third quarter 2026 earnings conference call on Thursday, October 29, 2026, at 10 a.m. Eastern Time. The call will follow the company's release of its earnings results earlier that morning at 8:00 a.m. Eastern Time.
Access details for the earnings call
Investors and analysts can participate in the live conference call using the following dial-in numbers:
| Region | Dial-in Number |
|---|---|
| U.S. & Canada | (877) 407-0890 |
| International | +1 (201) 389-0918 |
Participants should request the TriMas Third Quarter 2026 Earnings Call. A live webcast and presentation slides will be available on the company's website under the Investors section.
Replay availability
For those unable to attend the live session, a replay will be accessible from October 29 to November 11. The replay can be accessed via the following methods:
- U.S. & Canada: (877) 660-6853
- International: +1 (201) 612-7415
- Meeting ID: 13763096
Alternatively, the replay will be hosted on the Investors section of the company's official website.
About TriMas
TriMas designs, manufactures and supplies a broad range of innovative and high-quality products for the consumer packaging, life sciences and industrial markets through its TriMas Packaging and Specialty Products groups. The company employs approximately 2,500 people across 12 countries.
Headquartered in Bloomfield Hills, Michigan, TriMas focuses on empowering customer success through deep partnerships, technical expertise, focused innovation, and exceptional quality. The company is publicly traded on NASDAQ.
How will TriMas's Q3 2026 results reflect the impact of global supply chain disruptions on its packaging and specialty products segments?
What specific guidance is management expected to provide regarding capital allocation strategies following the Q3 earnings release?
How might recent regulatory changes in the life sciences sector influence TriMas's growth outlook for its Specialty Products group?




























